文献速递湿疹皮炎与荨麻疹

IGAxBSA复合评分用于评估特应性皮炎患者的疾病严重程度和治疗反应

IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
PubMed 文献 · Br J Dermatol · 2022-02-25

该研究基于度普利尤单抗临床试验项目汇总数据的回顾性分析,纳入随机对照试验(n=3473)和开放标签扩展试验(n=3045)的成人和儿童中重度特应性皮炎患者,评估IGAxBSA复合评分与EASI、SCORAD的相关性。结果显示IGAxBSA与EASI和SCORAD相关性良好,不受治疗组和种族影响,与EASI和SCORAD评估疾病随时间变化的相关性分别为r=0.90和r=0.76(P<0.0001),IGAxBSA-50/75/90与EASI-50/75/90的一致性为88-94%。结论认为IGAxBSA是评估特应性皮炎严重程度和治疗反应的有效替代工具。

要点

  • IGAxBSA与EASI和SCORAD相关性良好,不受治疗组和种族影响。
  • IGAxBSA与EASI和SCORAD评估疾病变化的相关性分别为r=0.90和r=0.76(P<0.0001)。
  • IGAxBSA-50/75/90与EASI-50/75/90的一致性为88-94%。

核心结论

  • IGAxBSA是评估特应性皮炎疾病严重程度和治疗反应的有效替代工具,与EASI或SCORAD相比,不受种族影响。

研究设计与样本

  • 对度普利尤单抗临床试验项目汇总数据的回顾性分析,纳入随机对照试验(n=3473)和开放标签扩展试验(n=3045)的成人和儿童中重度特应性皮炎患者,接受度普利尤单抗或安慰剂,联合或不联合外用糖皮质激素(TCS)。

主要发现

  • IGAxBSA与EASI和SCORAD相关性良好,不受治疗组和种族(白人、亚洲人、黑人)影响。
  • IGAxBSA与客观指标(EASI、SCORAD)的相关性优于与患者或照护者报告的主观指标的相关性。
  • IGAxBSA与EASI和SCORAD在评估疾病随时间变化方面相关性很强(分别为r=0.90和r=0.76;P<0.0001)。
  • IGAxBSA-50/75/90与EASI-50/75/90之间的一致性极好(88-94%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate assessment of atopic dermatitis (AD) severity is critical when initiating and monitoring therapy. Use of existing research tools such as the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD) is complex and time-consuming in clinical practice. A previous analysis found the product of validated Investigator's Global Assessment (vIGA) and affected body surface area (BSA) to be an accurate and practical tool for routine assessment of paediatric AD. OBJECTIVE: To evaluate the IGAxBSA composite as an alternative to EASI or SCORAD for assessment of AD disease severity and disease responsiveness. METHODS: The relationship between IGAxBSA, EASI and SCORAD was assessed in a post hoc analysis of pooled data from the dupilumab clinical trial programme in adult and paediatric patients with moderate-to-severe AD who had received dupilumab or placebo, with or without topical corticosteroids (TCS). The trials are registered at ClinicalTrials.gov and EudraCT: LIBERTY AD SOLO 1 (NCT02277743, 2014-001198-15), LIBERTY AD SOLO 2 (NCT02277769, 2014-002619-40), LIBERTY AD SOLO-CONTINUE (NCT02395133, 2014-003384-38), LIBERTY AD CHRONOS (NCT02260986, 2013-003254-24), LIBERTY AD CAFÉ (NCT02755649, 2015-002653-35), LIBERTY AD ADOL (NCT03054428, 2015-004458-16), LIBERTY AD PEDS (NCT03345914, 2016-004997-16), LIBERTY AD OLE (NCT01949311, 2013-001449-15) and LIBERTY AD PEDS OLE (NCT02612454, 2015-001396-40). RESULTS: Using datapoints from pooled dupilumab randomized controlled trials (n = 3473) and open-label extension trials (n = 3045), we found that IGAxBSA correlated well with EASI and SCORAD, irrespective of treatment group and race (white, Asian, black). IGAxBSA correlated better with objective measures (EASI, SCORAD) than with patient- or caregiver-reported subjective measures. IGAxBSA correlated strongly with EASI and SCORAD in assessing disease change over time (r = 0·90, r = 0·76, respectively; P < 0·0001), and concordance between IGAxBSA-50/75/90 and EASI-50/75/90 was excellent (88-94%). CONCLUSIONS: IGAxBSA is a valid alternative for assessment of AD disease severity and response over time, compared with EASI or SCORAD in patients with AD, irrespective of race.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Tan JKL, Bagel J, et al. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. Br J Dermatol. 2022. PMID: 34726270. doi:10.1111/bjd.20872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。